AGL 40.01 Increased By ▲ 0.01 (0.03%)
AIRLINK 129.40 Decreased By ▼ -0.13 (-0.1%)
BOP 6.73 Increased By ▲ 0.05 (0.75%)
CNERGY 4.47 Decreased By ▼ -0.16 (-3.46%)
DCL 8.60 Decreased By ▼ -0.34 (-3.8%)
DFML 40.99 Decreased By ▼ -0.70 (-1.68%)
DGKC 81.38 Decreased By ▼ -2.39 (-2.85%)
FCCL 32.75 Decreased By ▼ -0.02 (-0.06%)
FFBL 74.50 Decreased By ▼ -0.97 (-1.29%)
FFL 11.68 Increased By ▲ 0.21 (1.83%)
HUBC 109.50 Decreased By ▼ -1.05 (-0.95%)
HUMNL 13.75 Decreased By ▼ -0.81 (-5.56%)
KEL 5.34 Decreased By ▼ -0.05 (-0.93%)
KOSM 7.64 Decreased By ▼ -0.76 (-9.05%)
MLCF 38.50 Decreased By ▼ -1.29 (-3.24%)
NBP 63.75 Increased By ▲ 3.46 (5.74%)
OGDC 193.99 Decreased By ▼ -5.67 (-2.84%)
PAEL 25.65 Decreased By ▼ -1.00 (-3.75%)
PIBTL 7.38 Decreased By ▼ -0.28 (-3.66%)
PPL 154.80 Decreased By ▼ -3.12 (-1.98%)
PRL 25.90 Decreased By ▼ -0.83 (-3.11%)
PTC 17.52 Decreased By ▼ -0.94 (-5.09%)
SEARL 78.70 Decreased By ▼ -3.74 (-4.54%)
TELE 7.87 Decreased By ▼ -0.44 (-5.29%)
TOMCL 33.80 Decreased By ▼ -0.71 (-2.06%)
TPLP 8.46 Decreased By ▼ -0.60 (-6.62%)
TREET 16.26 Decreased By ▼ -1.21 (-6.93%)
TRG 58.40 Decreased By ▼ -2.92 (-4.76%)
UNITY 27.47 Increased By ▲ 0.04 (0.15%)
WTL 1.39 Increased By ▲ 0.01 (0.72%)
BR100 10,437 Increased By 30.4 (0.29%)
BR30 31,167 Decreased By -546.6 (-1.72%)
KSE100 97,794 Increased By 465.8 (0.48%)
KSE30 30,451 Increased By 259 (0.86%)
Business & Finance

Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation

  • "We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
  • "We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
Published April 13, 2021

NEW DELHI: Pfizer Inc said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech to India after the government eased import rules, after withdrawing its application in February.

"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.

"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."

Comments

Comments are closed.